Precision and personalized medicine (PPM) has already begun to reshape disease treatment paradigms and the provision of healthcare.
Gene-modified cell therapies are emerging as a cornerstone modality within PPM.
Cell therapies are entering a rapid growth phase across oncology and regenerative medicine.
Gene therapy remains a blockbuster-led modality with expanding therapeutic reach.
Antisense oligonucleotides are emerging as a fast-growing modality within PPM.
Oncolytic virus therapies show emerging commercial traction but remain a niche modality.
Core precision medicine enablers are strengthening adoption.
Gene-modified cell therapies are emerging as a cornerstone modality within PPM.
Cell therapies are entering a rapid growth phase across oncology and regenerative medicine.
Gene therapy remains a blockbuster-led modality with expanding therapeutic reach.
Antisense oligonucleotides are emerging as a fast-growing modality within PPM.
Oncolytic virus therapies show emerging commercial traction but remain a niche modality.
Core precision medicine enablers are strengthening adoption.
Report Scope
- This report talks about how precision and personalized medicine (PPM) has already begun to reshape disease treatment paradigms and the provision of healthcare.
- Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space.
Table of Contents
- Executive Summary
- Introduction
- Market Overview
- Gene-Modified Cell Therapies
- Cell Therapies
- Gene Therapies
- Antisense Oligonucleotides
- Oncolytic Viruses
- Case Studies
- Important Factors to Consider
- CGT Market
- Genomics
- Biomarkers
- Key Takeaways
- Appendix
